Patent ID: 7375227

Claim:
A compound of general formula 1, wherein: Py represents pyridin-4-yl mono-substituted in position 2 with —NR 2 R 3 ; pyridin-4-yl disubstituted in position 2 with —NR 2 R 3 and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; X represents aryl; aryl-O—; arylalkyl-; lower alkyl-SO 2 NR 2 —; aryl-SO 2 NR 2 —; arylalkyl-SO 2 NR 2 —; lower alkyl-CONR 2 —; aryl-CONR 2 —; arylalkyl-CONR 2 —; lower alkyl-NR 3 CONR 2 —; aryl-NR 3 CONR 2 —; arylalkyl-NR 3 CONR 2 —; aryl-CO—; arylalkyl-CO—; lower alkyl-NR 2 CO—;aryl-NR 2 CO—; or arylalkyl-NR 2 CO—; Y represents —C(R 4 )(R 5 )(CH 2 ) m — or —(CH 2 ) m C(R 4 )(R 5 )—; Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-CONR 2 —, lower alkyl-NR 2 CO—, aryl-NR 2 CO— or arylalkyl-NR 2 CO—; n represents the number 0 or 1; m represents the number 1 or 2; R 1 represents hydrogen or lower alkyl; R 2 and R 3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R 2 and R 3 are attached to the same nitrogen atom, R 2 and R 3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring; R 4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R 5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R 4 and R 5 are attached as ring atoms; and R 5 represents hydrogen, methyl, or forms together with R 4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R 4 and R 5 are attached as ring atoms, or an optically pure enantiomer or diastereomer, a mixture of enantiomers or diastereomers, a diastereomeric racemate, and a mixture of diastereomeric racemates; or a pharmaceutically acceptable salt, of said compound.